Literature DB >> 8528274

A slow acetylator genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome.

P Wolkenstein1, V Carrière, D Charue, S Bastuji-Garin, J Revuz, J C Roujeau, P Beaune, M Bagot.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8528274     DOI： 10.1097/00008571-199508000-00011

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN： 0960-314X


× No keyword cloud information.
  23 in total

Review 1.  [Pharmacogenetics].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2010-08       Impact factor: 0.751

Review 2.  [Pharmacogenetics: Important aspects for dermatology].

Authors:  H F Merk
Journal:  Hautarzt       Date:  2005-01       Impact factor: 0.751

3.  Evaluation of polymorphisms in the sulfonamide detoxification genes CYB5A and CYB5R3 in dogs with sulfonamide hypersensitivity.

Authors:  J Funk-Keenan; J Sacco; Y Y Amos Wong; S Rasmussen; A Motsinger-Reif; L A Trepanier
Journal:  J Vet Intern Med       Date:  2012-07-21       Impact factor: 3.333

4.  [Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report].

Authors:  T K Hoffmann; S von Schmiedeberg; M Wulferink; R Thier; H Bier; T Ruzicka; P Lehmann
Journal:  Hautarzt       Date:  2005-07       Impact factor: 0.751

5.  Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity.

Authors:  Danxin Wang; Michael F Para; Susan L Koletar; Wolfgang Sadee
Journal:  Pharmacogenet Genomics       Date:  2011-10       Impact factor: 2.089

6.  Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity.

Authors:  Ana Alfirevic; Anne C Stalford; F Javier Vilar; Ed G L Wilkins; B Kevin Park; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2003-02       Impact factor: 4.335

7.  New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited.

Authors:  Philippe Paquet; Gérald E Piérard
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

Review 8.  Drug-induced severe skin reactions. Incidence, management and prevention.

Authors:  P Wolkenstein; J Revuz
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

9.  Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity.

Authors:  James C Sacco; Mahmoud Abouraya; Alison Motsinger-Reif; Steven H Yale; Catherine A McCarty; Lauren A Trepanier
Journal:  Pharmacogenet Genomics       Date:  2012-10       Impact factor: 2.089

10.  Oral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome.

Authors:  Radhika Kumar; Claes H Dohlman; James Chodosh
Journal:  BMC Res Notes       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.